Page 1 | Search Results | Blood | American Society of Hematology

1-11 of 11

Sort by

Sort Order Select

Journal Articles

Reverting Rivaroxaban Effect By Activated Factor X: Assessment Using Thrombin Generation Assay

Dominique Grenier, Meyer Michel Samama, Professor, Sami Chtourou, Ph. D., Jean-Luc Plantier, PhD

Blood (2014) 124 (21): 2868.

https://doi.org/10.1182/blood.V124.21.2868.2868

Published: 2014

Journal Articles

What Is The Best Time Sampling For The Two Direct Oral Anticoagulants, Dabigatran and Rivaroxaban?

Jonathan Douxfils, Pharm D, PhD, Jean-Francois Classen, Pharm.Biol., Justine Baudar, Bérangère Devalet, M.D., Meyer Michel Samama, Bernard Chatelain, Jean-Michel Dogné, François Mullier, PhD

Blood (2013) 122 (21): 4805.

https://doi.org/10.1182/blood.V122.21.4805.4805

Published: 2013

Journal Articles

Evaluation of the Anti-Factor Xa Chromogenic Assay for Measuring Rivaroxaban Plasma Concentrations Using Calibrators and Controls

Meyer Michel Samama, Genevieve Contant, Theodore E Spiro, Elisabeth Perzborn, Céline Guinet, Yves Gourmelin, Léna Le Flem, Jean Luc Martinoli

Blood (2010) 116 (21): 3330.

https://doi.org/10.1182/blood.V116.21.3330.3330

Published: 2010

Journal Articles

Structural Determinants of Enoxaparin Oligosaccharides for the Down-Regulation of Tissue Factor Induced Factor VIIa Generation In Human Plasma.

Grigoris T Gerotziafas, Tahar Chakroun, Vassiliki Galea, Meyer Michel Samama, MD, Ismail Elalamy

Blood (2010) 116 (21): 1106.

https://doi.org/10.1182/blood.V116.21.1106.1106

Published: 2010

Journal Articles

Effects of the Novel, Oral, Direct Factor Xa Inhibitor Rivaroxaban on Coagulation Assays

Meyer Michel Samama, Lena Le Flem, Celine Guinet, Elisabeth Perzborn, Jean-Luc Martinoli, François Depasse

Blood (2008) 112 (11): 3028.

https://doi.org/10.1182/blood.V112.11.3028.3028

Published: 2008

Journal Articles

Venous Thromboembolism Risk in Stroke Patients Receiving Extended-Duration Enoxaparin Prophylaxis: Sub-Analysis of the EXCLAIM Study

Alexander GG Turpie, MD, Russell D Hull, MBBS, Sebastian M Schellong, MD, Victor F Tapson, MD, Manuel Monreal, MD, Meyer Michel Samama, MD, PharmD, Roger D Yusen, MD, MPH

Blood (2008) 112 (11): 433.

https://doi.org/10.1182/blood.V112.11.433.433

Published: 2008

Journal Articles

The Unmet Need for Extended Thromboprophylaxis in Acutely Ill Medical Patients: The Findings of IMPROVE, ENDORSE and EXCLAIM.

Frederick A Anderson, Jr., PhD, Russell D Hull, MBBS, Sebastian M Schellong, MD, Bruno Deslandes, Victor F Tapson, MD, Meyer Michel Samama, MD, PharmD, Alexander GG Turpie, MD, Roger D Yusen, MD, MPH, Herve Decousus, MD, Alexander T Cohen, MBBS, MSc, MD, FRACP, Manuel Monreal, MD

Blood (2008) 112 (11): 1981.

https://doi.org/10.1182/blood.V112.11.1981.1981

Published: 2008

Journal Articles

The Effects of the Degree of Mobility Reduction and Prespecified Risk Factors on Venous Thromboembolism Rates in Acutely Ill Medical Patients in the EXCLAIM Study.

Roger D. Yusen, Russell D. Hull, Sebastian M. Schellong, Victor F. Tapson, Manuel Monreal, Meyer-Michel Samama, Alexander G.G. Turpie

Blood (2007) 110 (11): 1862.

https://doi.org/10.1182/blood.V110.11.1862.1862

Published: 2007

Journal Articles

Consistent Venous Thromboembolism Risk Reduction by Extended- Versus Standard-Duration Enoxaparin Prophylaxis in Subgroups of Acutely Ill Medical Patients in the EXCLAIM Study.

Victor F. Tapson, Russell D. Hull, Sebastian M. Schellong, Manuel Monreal, Meyer-Michel Samama, Alexander G.G. Turpie, Roger D. Yusen

Blood (2007) 110 (11): 1863.

https://doi.org/10.1182/blood.V110.11.1863.1863

Published: 2007

Journal Articles

Extended-Duration Enoxaparin for Venous Thromboembolism Prophylaxis in Acutely Ill Medical Patients: An Evaluation of the EXCLAIM Study Based on a Recently Recommended Composite Efficacy Endpoint.

Sebastian M. Schellong, Russell D. Hull, Victor F. Tapson, Manuel Monreal, Meyer-Michel Samama, Alexander G.G. Turpie, Roger D. Yusen

Blood (2007) 110 (11): 1870.

https://doi.org/10.1182/blood.V110.11.1870.1870

Published: 2007

Journal Articles

Endogenous Thrombin Potential (ETP) in Patients with Hereditary Antithrombin (AT) Deficiency or Carriers of the Prothrombin (PT) 20210A Gene Mutation.

Jacqueline Conard, PhD, Nicolas Soustelle, Laura Plouy, Marie-Helene Horellou, MD, Meyer-Michel Samama, MD

Blood (2007) 110 (11): 1623.

https://doi.org/10.1182/blood.V110.11.1623.1623

Published: 2007

NARROW

Reverting Rivaroxaban Effect By Activated Factor X: Assessment Using Thrombin Generation Assay

What Is The Best Time Sampling For The Two Direct Oral Anticoagulants, Dabigatran and Rivaroxaban?

Evaluation of the Anti-Factor Xa Chromogenic Assay for Measuring Rivaroxaban Plasma Concentrations Using Calibrators and Controls

Structural Determinants of Enoxaparin Oligosaccharides for the Down-Regulation of Tissue Factor Induced Factor VIIa Generation In Human Plasma.

Effects of the Novel, Oral, Direct Factor Xa Inhibitor Rivaroxaban on Coagulation Assays

Venous Thromboembolism Risk in Stroke Patients Receiving Extended-Duration Enoxaparin Prophylaxis: Sub-Analysis of the EXCLAIM Study

The Unmet Need for Extended Thromboprophylaxis in Acutely Ill Medical Patients: The Findings of IMPROVE, ENDORSE and EXCLAIM.

The Effects of the Degree of Mobility Reduction and Prespecified Risk Factors on Venous Thromboembolism Rates in Acutely Ill Medical Patients in the EXCLAIM Study.

Consistent Venous Thromboembolism Risk Reduction by Extended- Versus Standard-Duration Enoxaparin Prophylaxis in Subgroups of Acutely Ill Medical Patients in the EXCLAIM Study.

Extended-Duration Enoxaparin for Venous Thromboembolism Prophylaxis in Acutely Ill Medical Patients: An Evaluation of the EXCLAIM Study Based on a Recently Recommended Composite Efficacy Endpoint.

Endogenous Thrombin Potential (ETP) in Patients with Hereditary Antithrombin (AT) Deficiency or Carriers of the Prothrombin (PT) 20210A Gene Mutation.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only